find a phd in neurodegenerative diseases

CNDR at the University of Pennsylvania brings together researchers investigating the causes and mechanisms of neurodegenerative diseases that occur more frequently with advancing age, such as:

• Alzheimer's disease (AD)
• Parkinson's disease (PD)
• other Lewy Body Disorders (LBD)
• Frontotemporal Lobar Degeneration (FTD)
• Frontotemporal Disease with Parkinsonism (FTDP-17)
• Amyotrophic Lateral Sclerosis (ALS)
• Primary Lateral Sclerosis (PLS)
• other Motor Neuron Diseases

With laboratories located on three floors of the Hospital of the University of Pennsylvania's Maloney Building (floors 1, 3 and 6), CNDR is in the heart of Penn's campus. CNDR scientists collaborate with researchers not only at Penn, but also from institutions around the globe to find better ways to diagnose and treat neurodegenerative disorders.

Founded in 1991, CNDR became the first and only National Institutes of Health (NIH)-funded Alzheimer's Disease Core Center (ADCC) in the Delaware Valley, part of a network of several cooperating NIH-funded centers throughout the nation. CNDR continues to lead the Penn ADCC and in 2019 the team launched a new  National Institute on Aging Penn U19: A Center on Alpha-Synuclein Strains in Alzheimer's Disease and Related Dementias.

More than 20 years ago, the team identified the significance of tau in Alzheimer's disease, later identifying TDP-43's role in other neurodegenerative diseases. More recently, the team has shown, first in Parkinson's, how pathology spreads from cell-to-cell in neurodegenerative diseases. Since its founding, CNDR has contributed to a dramatic expansion in basic and clinical research programs on neurodegenerative disorders at Penn. 

CNDR provides leadership, training/education, and core support to augment and enhance ongoing collaborative studies as well as to stimulate new investigations into the etiology, pathogenesis, diagnosis, treatment, and prevention of neurodegenerative diseases - and to translate progress in the lab to clinical practice. Researchers pursue a comprehensive array of research activities that extend from basic science methods of test tubes and cell culture systems to those involving animal models of neurodegenerative diseases.

Neuroscience Ph.D. Program

Our Neuroscience Ph.D. Program is one of the best in the nation, and prepares students to become independent researchers, educators and trainers making significant contributions across all aspects of the field.

Program Overview

Our program combines rigorous coursework and sound training in the fundamentals of neuroscience, including the integrated study of nervous system function and disease, with opportunities for state-of-the-art research. 

Please reach out to Bruce Carter if you have any questions about the Neuroscience Ph.D. Program or the application process.

Bruce Carter

Director of Graduate Studies in Neuroscience

Associate Director for Education and Training, Vanderbilt Brain Institute Professor of Biochemistry

• 615-936-3041
• 625 Light Hall

View profile

We foster the development from trainee to independent research scientist and educator.

Individualized Attention

With 81 graduate students and 64 training faculty, our excellent student-teacher ratio results in extensive opportunities for interaction and exchange of ideas in a relaxed and collegial atmosphere. Our distinguished training faculty stem from diverse fields such as Psychology, Biochemistry, Molecular Physiology, and Pharmacology and capture the multidisciplinary nature of modern neurobiological inquiry.

Career Outlook

Graduates of our department are superbly prepared for a variety of career options in both academia and industry. Each student's program is designed to provide a broad-based education in neuroscience, yet accommodate individual needs and interests to allow students to become creative, independent scientists.

Students holding degrees in the biological or physical sciences, psychology, or biomedical engineering are especially encouraged to apply to the Neuroscience Ph.D. Program, but applicants from other fields will be considered.

Areas of Concentration

The Neuroscience Ph.D program offers two areas of concentration. Students have the option to emphasize either Cellular & Molecular or Cognitive & Systems neuroscience, preparing each trainee for a future in which neuroscientists must be able to navigate from molecules to cells to neural systems and behavior.

Cognitive & Systems

This path provides doctoral training with emphasis on cognitive neuroscience, sensory-motor systems, neuroimaging, neural development, synaptic plasticity, neurobiological basis of neuropsychiatric and neurodegenerative disorders, and targeted gene disruption in transgenic animals to ascertain the function of neural genes and establish disease models.

Cellular & Molecular

This path provides doctoral training with emphasis on neurogenetics and genetic dissection of neural development, molecular aspects of synapse formation and plasticity, structure and regulation of ion channels and transporters, targeting and signal transduction, psychotropic drug action, the molecular basis of neuropsychiatric and neurodegenerative disorders, and targeted gene disruption in transgenic animals to ascertain the function of neural genes and establish disease models.

Cellular & Molecular Application Tip

Students with broad biomedical interests are encouraged to apply through the Interdisciplinary Graduate Program in Biological and Biomedical Sciences instead of directly through the Neuroscience Ph.D. Program. This pathways provides a strong foundation in biomedical science prior to matriculation into neuroscience.

Students begin their first year with a general course in graduate level cellular and molecular biology and then begin specialized courses in Neuroscience in the spring semester of their first year.

Grants and Awards

University Tuition Scholarships are service-free awards that pay all or part of tuition costs. The following graduate awards are normally supplemented by a full University Tuition Scholarship, which usually includes student health insurance coverage:

• University Fellowships
• Graduate Teaching Assistantships
• Graduate Research Assistantships
• Traineeships
• Teacher Training Awards

The current stipend level for 2023-2024 is $36,500. In addition, applicants may be nominated at the time of application for Harold S. Vanderbilt graduate scholarships and other awards, which provide an additional stipend of up to $10,000 per year to students of exceptional accomplishment and high promise.

Training in Fundamental Neuroscience T32 Grant

The Neuroscience Graduate Program receives invaluable support from the "Training in Fundamental Neuroscience" NIH T32. Over 70 mentors across 22 departments within 4 schools and colleges are available to train students, with 65+ Neuroscience trainees earning PhDs in the past 5 years. Over 60 trainees have been supported by the T32 since its inception, with over a third subsequently securing their own fellowship funding. Program graduates have gone on to leadership positions in academia, industry, and additional research-related fields, providing a rich alumni network across multiple career tracks. The program includes works-in-progress seminars by all Neuroscience trainees, invited external seminar speakers including several suggested or hosted by trainees, and an annual retreat.

Graduate students interested in joining the training program should contact Dr. Bruce Carter, Associate Director for Education & Training and Director of Graduate Studies for the VBI.

Faculty interested in becoming T32 preceptors should contact Dr. Rebecca A. Ihrie or Dr. Lisa Monteggia, VBI Director.

Rebecca A. Ihrie

Associate Professor, Cell & Developmental Biology and Neurological Surgery

• 615-936-2951
• B2317 Medical Center North

View Profile

Graduate students in the Neuroscience Graduate program receiving Vanderbilt University financial support or services must devote full-time effort to graduate study. Students cannot accept jobs for pay within or outside the University unless prior approval is given by their advisor, their Director of Graduate Studies, and the Dean for the Office of Biomedical Research Education and Training. Exceptions to this rule include part-time internships and activities that contribute to career development and that do not exceed the time commitment outlined by the National Institutes of Health, service as course associates at Vanderbilt, and occasional and temporary part-time pursuits (e.g. house sitting). Engagement in outside employment without obtaining approval may result in loss of financial aid, including stipend.

General Inquiries

Call today to schedule an appointment or fill out an online request form. If requested before 2 p.m. you will receive a response today.

713-798-1000

Monday - Friday 8 a.m. - 5 p.m.

Request Now

Request non-urgent appointments

Find a Physician

America's fourth largest city is a great place to live, work and play. Find out why. Get to Know Houston

Give Careers Intranet

• Graduate School of Biomedical Sciences
• Degree Programs and Certificates
• Current Students
• Postdoctoral Affairs
• Faculty Mentoring Resources
• Connect with GSBS
• Graduate School Contacts
• Career Paths
• Student Life
• Training Grants
• Faculty & Staff
• Baylor College of Medicine
• Development, Disease Models & Therapeutics Graduate Program
• Faculty Research by Disease
• Neurodegenerative Disease & Dementia

Neurodegenerative Disease and Dementia

Faculty profiles: neurodegenerative disease and dementia.

MD Anderson Cancer Center

• Randy L. Johnson, Ph.D.

Texas A&M University

• David Reiner, Ph.D.

Graduate School Admissions

Find all the information you need to apply to the Baylor College of Medicine Graduate School of Biomedical Sciences.

• Institute Trustees
• History & Legacy
• Publications
• About Research
• Research Areas
• Research Departments
• Core Technologies and Services
• Postdoctoral Program
• Collaborations
• Technologies and Tools
• Research Internships
• Research Board of Trustees & External Scientific Advisory Board
• About the Graduate School
• VAI Graduate School Board of Directors
• Doctoral Program
• Leadership and Staff
• Current Students
• Student Life
• Outcome Data
• About K-12 Education
• For Families
• For Educators
• Inquiry Insider
• About Support
• Ways to Give
• Ways to Support
• Purple Community
• Donor Stories

Get the latest stories right in your inbox.

Neuro­degenerative science.

Worldwide, between 7 million and 10 million people have Parkinson’s disease and more than 30 million have dementia . Currently, there is no cure and no effective way to slow or stop disease progression.

VAI scientists aim to change that by investigating the complex factors that give rise to neurodegenerative and psychiatric disorders, from genetics and epigenetics to aging, inflammation and the structure of the brain itself — even the role of the gut and the immune system. By leveraging discoveries made in VAI’s labs and collaborating with researchers around the world, our scientists are working to translate breakthroughs into life-changing new treatments for Parkinson’s, dementias and depression .

West Michigan Neurodegenerative Diseases (MiND) Program

Van Andel Institute’s West Michigan Neurodegenerative Diseases (MiND) Program is a collaborative effort to identify genetic and epigenetic changes that may play roles in neurodegenerative diseases, such as Parkinson’s and dementias. Our goal? To move the needle in our understanding of these diseases, power new discoveries and leverage our findings to inform groundbreaking treatment strategies.

Our Faculty

Darren Moore, Ph.D.

Chair and Professor, Department of Neurodegenerative Science; Director, MiND Program

Molecular Neurodegeneration

Lena Brundin, M.D., Ph.D.

Professor, Department of Neurodegenerative Science

Behavioral Medicine

Gerhard (Gerry) Coetzee, Ph.D.

Post-GWAS Functionality

Michael Henderson, Ph.D.

Assistant Professor, Department of Neurodegenerative Science

Protein Pathologies and Genetic Risk in Neurodegeneration

Laurent Roybon, Ph.D.

Associate Professor, Department of Neurodegenerative Science; Director, MiND iPSC Program

Qiang Zhu, Ph.D.

Genetics, Epigenetics and Therapeutic Innovation in Neurodegenerative Diseases

Area of Expertise

West michigan neuro­degenerative disease (mind) program staff.

Erin Williams, Ph.D.

Research Program Manager, MiND

Arianna Colini Baldeschi, Ph.D.

Postdoctoral Fellow, Roybon Laboratory

Ashley Douglass, B.S.

Senior Administrative Assistant II

Maxwell Frye

Assistant Research Technician, MiND Program

Olivia Licari

Research Technician, MiND Program

Estibaliz Santiago-Mujika, Ph.D.

MiND iPSC Platform

Latest from Vai

Scientists identify cell vulnerability ‘fingerprint’ related to parkinson’s, lewy body dementia, van andel institute to recognize eminent parkinson’s disease scientist dr. anders björklund with 2024 jay van andel award, phase 2 clinical trial of type 2 diabetes drug for treatment of parkinson’s shows positive and promising results, van andel institute announces 2024 public lecture series, recent tweets, recent publications.

* Co-first authors # Co-corresponding authors

We're raising thousands to save millions

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

• 121 peer-reviewed papers published in 2023
• 62 peer-reviewed papers published in high-impact journals in 2023
• 55 clinical trials launched to date

• skip to Cookie Notice
• skip to Main Navigation
• skip to Main Content
• skip to Footer
• Find a Doctor
• Find a Location
• Appointments & Referrals
• Patient Gateway
• Español
• Leadership Team
• Quality & Safety
• Equity & Inclusion
• Community Health
• Education & Training
• Centers & Departments
• Browse Treatments
• Browse Conditions A-Z
• View All Centers & Departments
• Clinical Trials
• Cancer Clinical Trials
• Cancer Center
• Digestive Healthcare Center
• Heart Center
• Mass General for Children
• Neuroscience
• Orthopaedic Surgery
• Information for Visitors
• Maps & Directions
• Parking & Shuttles
• Services & Amenities
• Accessibility
• Visiting Boston
• International Patients
• Medical Records
• Billing, Insurance & Financial Assistance
• Privacy & Security
• Patient Experience
• Explore Our Laboratories
• Industry Collaborations
• Research & Innovation News
• About the Research Institute
• Innovation Programs
• Education & Community Outreach
• Support Our Research
• Find a Researcher
• News & Events
• Ways to Give
• Patient Rights & Advocacy
• Website Terms of Use
• Apollo (Intranet)
• Like us on Facebook
• Follow us on Twitter
• See us on LinkedIn
• Print this page

Research Faculty at MIND

Mass General Institute for Neurodegenerative Disease (MIND) laboratories are run by faculty members who also hold appointments in their respective departments at Mass General Hospital. Principal Investigators hold MDs and/or PhDs and typically supervise laboratory personnel that include MD research fellows, postdoctoral fellows, graduate students, staff scientists and research technicians. MIND laboratory research interests are diverse, yet are united by the goal of understanding neurodegenerative disease and finding and translating laboratory discoveries into treatments and therapeutics for patients.

Mark Albers, MD, PhD

The sense of smell may provide important clues to help identify patients with neurodegenerative diseases before their symptoms emerge. Dr. Albers uses the olfactory system of mice and humans to help understand the early events of neurodegeneration in order to find ways to intervene early in the disease process before symptoms appear and distinguish early pathologic events from changes produced by aging.

About Dr. Albers -->     Albers Lab -->

Steven E. Arnold, MD

Dr. Arnold leads a broad clinical and translational research program on Alzheimer’s disease and other neurocognitive disorders of aging. His major interests include clinicopathological correlation studies of molecular markers in human cerebrospinal fluid and postmortem brain tissue, the discovery and validation of biochemical biomarkers for diagnosis and staging of neurodegenerative dementias, and the design and conduct of novel, early phase and proof-of-concept clinical trials.

Brian Bacskai, PhD

Dr. Bacskai uses optical techniques to ask fundamental questions in Alzheimer's disease research. Using the mulitphoton micrsocopy imaging technique, senile plaques of Alzheimer's disease can be detected and characterized in the brains of living transgenic mice. This approach was used to study a way to clear senile plaques based on immunotherapy, as well as to characterize new factors that target amyloid in preclinical development for PET imaging in humans.

Rachel Bennett, PhD

Dr. Bennett studies cell biology of the nervous system with a focus on understanding neurodegeneration in Alzheimer's disease. Her research uses in vivo imaging tools to visualize pathological tau accumulation and vascular dysfunction in experimental models.

Oksana Berezovska, PhD

Dr. Berezovska leads the Neurobilogy of Alzheimer’s disease research laboratory that studies cellular and molecular events leading to neuropathological changes in Alzheimer’s disease, with a particular focus on the synapse. The ratio of amyloid beta peptides that end in amino acid 42 as compared to amino acid 40 can be measured in the cerebrospinal fluid. An increase in the Abeta 42/40 ratio has been implicated in Alzheimer's disease (AD) pathogenesis.

Craig Blackstone, MD, PhD

Dr. Blackstone's research group investigates cellular mechanisms underlying inherited neurological disorders, with an emphasis on neuromuscular and movement disorders. In particular, the pathogenesis of hereditary spastic paraplegias, which affect corticospinal motor axons in a length-dependent manner, is an area of very active interest.

Xiqun Chen, MD, PhD

Trained in clinical and basic neuroscience, Dr. Chen studies the molecular biology of neurodegeneration in Parkinson’s disease (PD) and related disorders. Working with collaborators at Mass General, the Harvard School of Public Health, and overseas, Chen’s group is pursuing the biological basis of the epidemiological link between PD and melanoma. Studies have shown that Parkinson’s patients have a higher incidence of melanoma, and that melanoma patients have a higher risk of developing PD.

Se Hoon Choi, PhD

Dr. Choi studies the pathogenesis of Alzheimer's disease and the role of adult-generated neurons in the disease. The human hippocampus normally continues to generate new neurons into old age, but this process is impaired in Alzheimer's disease patients; his research into mouse and cell-culture models of the disease suggests that stimulating neurogenesis alone does not improve mental function but that it may be helpful in combination with other interventions.

Merit Cudkowicz, MD, MSc

Dr. Merit Cudkowicz is the Julieanne Dorn Professor of Neurology at Harvard Medical School and the Chief of the Neurology Service at Massachusetts General Hospital. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz directs the Sean M. Healey and AMG Center for ALS.

Marian DiFiglia, PhD

Dr. DiFiglia is a Professor of Neurology at Harvard Medical School and Director of the Laboratory of Cellular Neurobiology at MassGeneral Institute for Neurodegenerative Disease. Sheleads a multidisciplinary research team investigating the role of the Huntington’s disease mutation in the molecular and cellular events leading to neurodegeneration in Huntington’s disease (HD).

Teresa Gomez-Isla, MD

Dr. Gomez-Isla has specific clinical interests in Alzheimer's disease and other dementias. She sees patients with these disorders as part of clinical evaluation and care, as well as for research purposes. There is a great need to understand the mechanisms that lead to neural system collapse and impaired cognition in Alzheimer's disease and related disorders, and to find better treatments potentially able to prevent or cure this illness.

Stephen Gomperts, MD, PhD

Dr. Gomperts investigates Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies, as well as normal brain function, using both laboratory research and clinical research strategies. His laboratory research is focused on how populations of neurons in the hippocampus represent information, encode new memories, and coordinate with other brain structures in the service of behavior; and how to rescue the failure of those processes in neurologic diseases.

Ana Griciuc, PhD

Dr. Griciuc is exploring how CD33 , an innate immunity-related gene, serves as a pathogenetic risk factor in Alzheimer’s disease. Her research has shown that CD33 activity in microglia strongly impaired their ability to uptake and clear brain amyloid beta and has uncovered a novel pathway for amyloid beta clearance in the aging brain and Alzheimer's disease pathogenesis.

Steven Hersch, MD, PhD

Dr. Hersch’s research focuses on Huntington’s disease (HD) and helping to develop treatments to slow or cure this fatal progressive neurogenetic disorder. His laboratory works to discover and translate potential disease modifying therapies and biomarkers from the lab to the clinic.

Brad Hyman, MD, PhD

Dr. Hyman studies the anatomical and molecular basis of dementia in Alzheimer’s disease, and Dementia with Lewy Bodies. His research includes a collaborative of several labs working on different aspects of neurodegenerative disease and dementia. He also has a clinical practice in the Memory and Disorder Unit at the Massachusetts General Hospital devoted towards the care of patients with dementia.

Ksenia Kastanenka, PhD

Dr. Kastanenka studies aging, with particular emphasis on Alzheimer’s disease. Her laboratory focuses on circuitry disruption during the disease progression and mechanisms of action of Alzheimer’s therapeutics.

Kimberly Kegel, PhD

Dr. Kegel studies the normal and altered function of huntingtin (htt), the protein mutated in Huntington Disease (HD). Her early work revealed that autophagy and the lysosomal system were activated with htt accumulation in an HD cell system. More recently, she has discovered a normal association of htt with specific phosphoinositol phosphates (PIPs). PIPs are lipids present in membranes that can act to target proteins to specific sites within cells.

Doo Yeon Kim, PhD

Doo Yeon Kim, PhD studies pathogenic mechanisms of Alzheimer’s disease (AD) using both cellular and animal models. He and his team developed a three-dimensional (3D) human neural cell culture model of AD, which recapitulated key aspects of AD pathology including β-amyloid aggregation and β-amyloid-driven tau pathology. Dr. Kim’s lab also studies how Alzheimer’s beta-secretase, BACE1, regulates synaptic and axonal ion channel trafficking using cellular and mouse models.

Dora Kovacs, PhD

Dr. Kovacs researchers neurodegeneration in Alzheimer’s disease, focused on identifying cellular pathways regulating the generation of the toxic beta-amyloid protein (Abeta).

Clotilde Lagier-Tourenne, MD, PhD

Dr. Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and to develop therapeutic strategies. Mutations and/or cellular mislocalization of several RNA binding proteins have been identified as central components in the pathogenesis of ALS and FTD.

Jenny Linnoila, MD, PhD

Dr. Linnoila's research interests lie in better understanding the interaction between the immune and nervous systems. In particular, she is interested in the intersection between infectious and autoimmune neurology. She is currently working on establishing a rodent model of autoimmune encephalitis.

Laurie Ozelius, PhD

Dr. Ozelius works to uncover genetic causes for movement disorders, especially dystonias and Parkinson’s disease. Dystonias are characterized by involuntary muscle contractions that lead to slow movements or abnormal postures. Dystonias can be localized, as in writers’ cramp or torticollis, or generalized, and they often run in families.

Ghazaleh Sadri-Vakili, PhD

The NeuroEpigenetics laboratory at MIND, under the direction of Dr. Sadri-Vakili, studies the molecular mechanisms that underlie alterations in gene expression in disorders of the nervous system using the most current molecular biology tools. Currently, their efforts are focused on Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS) and addiction.

Michael Schwarzschild, MD, PhD

Dr. Schwarzschild's lab investigates molecular mechanisms in mouse models of Parkinson’s disease in an effort to develop improved therapies for neurodegenerative diseases. His research extends to the clinic where he conducts trials of novel treatments with the potential to slow progression of Parkinson’s disease.

Alberto Serrano Pozo, MD, PhD

Dr. Serrano Pozo's research focuses on trying to explain how the amyloid plaques and neurofibrillary tangles accumulate in the brain of Alzheimer’s disease patients and how they lead to dementia. In particular, he is interested in understanding the underlying mechanisms of glial responses and their effects on Alzheimer’s disease development and progression.

Nutan Sharma, MD, PhD

Dr. Sharma combines clinical expertise in movement disorders with research into the genetics and pathophysiology of dystonia. As founder and director of the dystonia clinic at Mass General, Dr. Sharma conducts systematic clinical evaluation of patients in a longitudinal study of the natural history of dystonia. She collaborates with MIND geneticists to identify new dystonia-causing genes, by collecting families with dystonia for careful clinical characterization and DNA analysis.

Jaehong Suh, PhD

Dr. Jaehong Suh studies the genetic and molecular mechanisms of Alzheimer’s disease (AD) and other neurodegenerative disorders, with the aim of identifying novel therapeutic targets and developing effective treatments for patients. Suh was involved in the identification of novel mutations from late-onset AD families in the prodomain of ADAM10, a major a-secretase that cleaves B-amyloid (AB region of amyloid precursor protein (APP)).

Rudolph Tanzi, PhD

Dr. Tanzi is the Vice-Chair of Neurology (Research) at Mass General and Director of the Genetics and Aging Research Unit at MIND. He is an elected "Professor Representative" to the Mass General Executive Committee on Research and serves as the Chair of the Cure Alzheimer's Fund Research Consortium, for which he spearheads the Alzheimer’s Genome Project.

Susanne Van Veluw, PhD

The Van Veluw lab studies the crosslinks between cerebral small vessel disease (SVD) and dementia. They use a combination of advanced neuroimaging techniques in human brain tissue and animal models to unravel the histopathological underpinnings of neuroimaging markers of SVD and to get at the pathophysiological mechanisms involved. 

Brian Wainger, MD, PhD

Dr. Wainger’s lab fuses electrophysiology and stem cell biology to explore how abnormal neuronal physiology contributes to diseases of the motor and sensory nervous systems. Working with motor neurons derived from ALS patients and healthy controls, Dr. Wainger performed fundamental electrophysiological characterization and identified motor neuron hyperexcitability in ALS patient-derived motor neurons.

Wilma Wasco, PhD

Dr. Wasco is interested in factors and events that surround the neuronal degeneration that is characteristic of Alzheimer's disease and normal aging. Her lab was involved in the identification and characterization the two presenilin proteins (PS1 and PS2), and her current focus is on identifying genes associated with the etiology of late onset Alzheimer’s disease.

Can (Martin) Zhang, MD, PhD

Dr. Zhang’s research is focused on identifying the mechanism of neurodegeneration in Alzheimer’s disease (AD), with the goal of identifying molecular targets and biomarkers that will translate into the development of novel therapeutic strategies for AD. The pathogenesis of AD is believed to be primarily driven by amyloid-B (AB), the principal component of senile plaques in the brain.

Clinical Trial Options at Mass General

At the Sean M. Healey and AMG Center for ALS, we are committed to radical change and acceleration of converting ALS research into enduring treatments.

Support MIND

Your contributions help drive discovery and propel findings from the laboratory bench into the clinic.

• History, Facts & Figures
• YSM Dean & Deputy Deans
• YSM Administration
• Department Chairs
• YSM Executive Group
• YSM Board of Permanent Officers
• FAC Documents
• Current FAC Members
• Appointments & Promotions Committees
• Ad Hoc Committees and Working Groups
• Chair Searches
• Leadership Searches
• Organization Charts
• Faculty Demographic Data
• Professionalism Reporting Data
• 2022 Diversity Engagement Survey
• State of the School Archive
• Faculty Climate Survey: YSM Results
• Strategic Planning
• Mission Statement & Process
• Beyond Sterling Hall
• COVID-19 Series Workshops
• Previous Workshops
• Departments & Centers
• Find People
• Biomedical Data Science
• Health Equity
• Inflammation
• Neuroscience
• Global Health
• Diabetes and Metabolism
• Policies & Procedures
• Media Relations
• A to Z YSM Lab Websites
• A-Z Faculty List
• A-Z Staff List
• A to Z Abbreviations
• Dept. Diversity Vice Chairs & Champions
• Dean’s Advisory Council on Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Affairs Website
• Minority Organization for Retention and Expansion Website
• Office for Women in Medicine and Science
• Committee on the Status of Women in Medicine Website
• Director of Scientist Diversity and Inclusion
• Diversity Supplements
• Frequently Asked Questions
• Recruitment
• By Department & Program
• News & Events
• Executive Committee
• Aperture: Women in Medicine
• Self-Reflection
• Portraits of Strength
• Mindful: Mental Health Through Art
• Event Photo Galleries
• Additional Support
• MD-PhD Program
• PA Online Program
• Joint MD Programs
• How to Apply
• Advanced Health Sciences Research
• Clinical Informatics & Data Science
• Clinical Investigation
• Medical Education
• Visiting Student Programs
• Special Programs & Student Opportunities
• Residency & Fellowship Programs
• Center for Med Ed
• Organizational Chart
• Leadership & Staff
• Committee Procedural Info (Login Required)
• Faculty Affairs Department Teams
• Recent Appointments & Promotions
• Academic Clinician Track
• Clinician Educator-Scholar Track
• Clinican-Scientist Track
• Investigator Track
• Traditional Track
• Research Ranks
• Instructor/Lecturer
• Social Work Ranks
• Voluntary Ranks
• Adjunct Ranks
• Other Appt Types
• Appointments
• Reappointments
• Transfer of Track
• Term Extensions
• Timeline for A&P Processes
• Interfolio Faculty Search
• Interfolio A&P Processes
• Yale CV Part 1 (CV1)
• Yale CV Part 2 (CV2)
• Samples of Scholarship
• Teaching Evaluations
• Letters of Evaluation
• Dept A&P Narrative
• A&P Voting
• Faculty Affairs Staff Pages
• OAPD Faculty Workshops
• Leadership & Development Seminars
• List of Faculty Mentors
• Incoming Faculty Orientation
• Faculty Onboarding
• Past YSM Award Recipients
• Past PA Award Recipients
• Past YM Award Recipients
• International Award Recipients
• Nominations Calendar
• OAPD Newsletter
• Fostering a Shared Vision of Professionalism
• Academic Integrity
• Addressing Professionalism Concerns
• Consultation Support for Chairs & Section Chiefs
• Policies & Codes of Conduct
• Health & Well-being
• First Fridays
• Fund for Physician-Scientist Mentorship
• Grant Library
• Grant Writing Course
• Mock Study Section
• Research Paper Writing
• Funding Opportunities
• Join Our Voluntary Faculty
• Child Mental Health: Fostering Wellness in Children
• Faculty Resources
• Research by Keyword
• Research by Department
• Research by Global Location
• Translational Research
• Research Cores & Services
• Program for the Promotion of Interdisciplinary Team Science (POINTS)
• CEnR Steering Committee
• Experiential Learning Subcommittee
• Goals & Objectives
• Issues List
• Print Magazine PDFs
• Print Newsletter PDFs
• YSM Events Newsletter
• Social Media
• Patient Care

INFORMATION FOR

• Residents & Fellows
• Researchers
• Neurodegenerative Diseases

Associate Professor Adjunct, Endocrinology

• Glioblastoma
• Ion Channels
• Mitochondria
• Neuronal Plasticity
• Neurosciences
• Parkinson Disease
• Developmental Biology
• Deep Brain Stimulation

Associate Professor Adjunct

• Cerebrovascular Disorders
• Migraine Disorders
• Schizophrenia, Childhood
• Malformations of Cortical Development
• Circulating Tumor DNA
• Human Genetics
• Genomic Medicine

Elizabeth Mears and House Jameson Professor of Psychiatry; Co-director, Science Fellows Program

• Biological Psychiatry

Associate Professor of Neurology and of Neuroscience

• Brain Diseases
• Demyelinating Diseases
• Spinal Cord Injuries

Associate Professor of Radiology & Biomedical Imaging and of Pharmacology

• Alzheimer Disease
• Chemistry, Pharmaceutical
• Pharmacokinetics
• Pharmacology
• Positron-Emission Tomography
• Drug Discovery
• Drug Development

Assistant Professor

• Autoimmune Diseases
• HLA Antigens
• Immunotherapy
• Major Histocompatibility Complex
• Mass Spectrometry
• Antigen Presentation
• Computational Biology
• Cancer Vaccines
• Microfluidics
• Systems Biology
• Infectious Disease Medicine
• Single-Cell Analysis
• Spatial Analysis
• Space Research

Assistant Professor of Public Health (Social and Behavioral Sciences) and Assistant Professor of Anthropology (Secondary)

• Qualitative Research
• Health Disparate, Minority and Vulnerable Populations
• Systemic Racism

Associate Research Scientist

• Cerebrospinal Fluid
• AIDS Dementia Complex
• Neurocognitive Disorders
• Neuroimaging

Associate Professor of Neurology and Neuroscience

• Neuronal Ceroid-Lipofuscinoses
• Receptors, Presynaptic

Assistant Professor of Psychiatry and of Neurology; Medical Director, Dementia and Behavioral Neurology, Neurology

Associate Professor of Neurology and Pharmacology

• Immune System
• Neurodevelopmental Disorders

Assistant Professor of Pathology

• Amyotrophic Lateral Sclerosis
• Cell Biology
• Ribonucleoproteins
• RNA Transport
• Frontotemporal Lobar Degeneration
• TDP-43 Proteinopathies

Dr. Harry M. Zimmerman and Dr. Nicholas and Viola Spinelli Professor of Neurology and Neuroscience; Vice-Chair for Research, Neurology; Director, Center for Experimental Neuroimaging

• Blood-Brain Barrier
• Capillaries
• Cerebrovascular Circulation
• Nerve Fibers, Myelinated
• Regional Blood Flow

Assistant Professor of Neuroscience; Co-Director of Graduate Studies, Interdepartmental Neuroscience Program

• Motor Neuron Disease
• RNA-Binding Proteins
• Frontotemporal Dementia
• High-Throughput Nucleotide Sequencing

Professor Emeritus of Cell Biology

• Education, Medical
• Endocrine System Diseases
• Molecular Biology
• Intercellular Signaling Peptides and Proteins
• Proteolysis

Sterling Professor of Genetics and Professor of Pediatrics

• Motor Neurons
• Superoxide Dismutase
• Protein Folding

Associate Professor of Genetics and Neuroscience; Member, Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR)

• Mental Disorders
• Developmental Disabilities
• Neuromuscular Diseases
• Spinocerebellar Ataxias

Associate Professor in Cell Biology

• Endoplasmic Reticulum
• Quality Control
• Ubiquitin-Protein Ligases
• Unfolded Protein Response

Associate Research Scientist in Neuroscience

• Embryo, Mammalian
• Interneurons
• Organizers, Embryonic
• Pluripotent Stem Cells
• Induced Pluripotent Stem Cells
• Neural Stem Cells
• Dopaminergic Neurons
• GABAergic Neurons

Assistant Professor Adjunct

• Synaptic Transmission
• ATP Synthetase Complexes
• alpha7 Nicotinic Acetylcholine Receptor

UCL Queen Square Institute of Neurology

4-year PhD Programme in Neurodegeneration 

For clinical and non-clinical fellows, funded by eisai, ltd and the wolfson foundation , please note that this programme has now stopped recruiting with the last in-take of students being in september 2020..

This is a four year programme consisting of taught courses and lab rotations in the first year, followed by the PhD research project in years two-four. The taught courses include:

1. Statistics and data analysis

2. Library and database usage

3. MSc modules, as required. (See MSc Dementia for examples) 

During the first year, students will also conduct three 10-12 week research projects at three different laboratories. Research projects will all have an industrial slant and will be divided into three broad themes:

1. Therapeutic Focus: Neurodegenerative diseases, e.g. Alzheimer’s, Parkinson’s, synucleinopathies and other related dementias  

2. Basic mechanisms and interventions, e.g. Proteinopathy / aggregation

3. Enabling Technologies / Platforms, e.g. ‘Disease-in-a-dish’ models of human disease (including iPSCs), Non-invasive translational biomarkers (e.g. fluid-based such as CSF, blood etc.) 

In each of the rotations, students will be expected to participate fully in the activities of the laboratories in which they are based, in order to gain an understanding of the practical research skills and knowledge in which that lab is expert.

The experience and knowledge gained through the taught courses and lab rotations will help students to identify their supervisor(s) and PhD project of interest, which they will then follow for the remaining three years of the programme. It is anticipated that students will have a large input into the development of interdiscplinary research projects, combining the projects undertaken during their lab rotations to develop new and innovative ideas.

In addition to the range of projects offered within UCL, there will be opportunities for students to take advantage of our close links with one of our funders,  Eisai , one of the world’s leading pharmaceutical research companies. Students will be able to engage in rotation projects and develop their PhD studies within their laboratories.

Non-clinical PhD Programme

This programme is aimed at graduates with a strong interest in multi-disciplinary research in neurodegeneration. Applications are invited from students whose first degree is in a biological, physical or chemical or other relevant discipline. Please note this is a strongly molecular PhD- those with psychology backgrounds may be better served in a different programme, although are welcome to apply. 

Entry requirements

You should have, or expect, a UK honours degree (minimum 2:1) or international equivalent, in relevant field as above. The UCL English Language proficiency requirement must have already been met at the time of application. 

Studentships cover UK/EU tuition fees and pay a generous tax-free stipend, starting at £22,278 in the first year [see Wellcome Trust funding rates for full details]. Students are also given an allowance of £4k for travel and £36k for project consumables. 

Applications from overseas students will be considered; however, you must provide evidence that you are able to cover the difference in tuition fees (only amounts up to EU fees are covered, but otherwise the studentship is the same). 

Non-clinical Applications

Please note that this programme is now closed and no longer recruiting.

Clinical Applications

Please note that this programme is now closed and no longer recruiting. 

Data science in neurodegenerative disease: its capabilities, limitations, and perspectives

Affiliations.

• 1 Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin.
• 2 Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
• PMID: 32073441
• PMCID: PMC7077964
• DOI: 10.1097/WCO.0000000000000795

Purpose of review: With the advancement of computational approaches and abundance of biomedical data, a broad range of neurodegenerative disease models have been developed. In this review, we argue that computational models can be both relevant and useful in neurodegenerative disease research and although the current established models have limitations in clinical practice, artificial intelligence has the potential to overcome deficiencies encountered by these models, which in turn can improve our understanding of disease.

Recent findings: In recent years, diverse computational approaches have been used to shed light on different aspects of neurodegenerative disease models. For example, linear and nonlinear mixed models, self-modeling regression, differential equation models, and event-based models have been applied to provide a better understanding of disease progression patterns and biomarker trajectories. Additionally, the Cox-regression technique, Bayesian network models, and deep-learning-based approaches have been used to predict the probability of future incidence of disease, whereas nonnegative matrix factorization, nonhierarchical cluster analysis, hierarchical agglomerative clustering, and deep-learning-based approaches have been employed to stratify patients based on their disease subtypes. Furthermore, the interpretation of neurodegenerative disease data is possible through knowledge-based models which use prior knowledge to complement data-driven analyses. These knowledge-based models can include pathway-centric approaches to establish pathways perturbed in a given condition, as well as disease-specific knowledge maps, which elucidate the mechanisms involved in a given disease. Collectively, these established models have revealed high granular details and insights into neurodegenerative disease models.

Summary: In conjunction with increasingly advanced computational approaches, a wide spectrum of neurodegenerative disease models, which can be broadly categorized into data-driven and knowledge-driven, have been developed. We review the state of the art data and knowledge-driven models and discuss the necessary steps which are vital to bring them into clinical application.

Publication types

• Research Support, Non-U.S. Gov't
• Data Science*
• Models, Statistical
• Neurodegenerative Diseases / epidemiology*

• Skip to main menu
• Skip to user menu

Postdoctoral research fellow focused on proteomics in neurodegenerative diseases

Postdoctoral research fellow in clinical memory research, focused on proteomics in neurodegenerative diseases

Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper Malmö

Lund University was founded in 1666 and is repeatedly ranked among the world’s top universities. The University has around 45 000 students and more than 8 000 staff based in Lund, Helsingborg and Malmö. We are united in our efforts to understand, explain and improve our world and the human condition.

Lund University welcomes applicants with diverse backgrounds and experiences. We regard gender equality and diversity as a strength and an asset.

Description of the workplace

We study the biological processes behind Alzheimer's disease (AD) and other neurodegenerative diseases. We work with cohorts of patients and cognitively healthy volunteers, who undergo extensive testing with brain imaging, biomarker measurements and neuropsychological testing, as well as animal and cell biology experiments. You can read more about the research  here . The research group is led by Professor Oskar Hansson. The position is located at BMC in Lund.

Neurodegenerative diseases are complex and multifaceted. The overarching goal of the project is to contribute to improved ability to diagnose, prognosticate, and stratify various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. The project also aims to provide new insights into disease mechanisms and relevant molecular signaling pathways in different conditions. We plan to achieve the project's objectives through proteomics, investigating a large number of proteins in blood and cerebrospinal fluid from patients and healthy controls.

The research will be conducted under the leadership of Professor Oskar Hansson, university lecturer Niklas Mattsson-Carlgren, and assistant university lecturer Jacob Vogel.

We care about creating a positive, respectful, and stimulating environment. We value communication and collaboration and a workplace that promotes learning and development for all employees. We are also committed to building a safe and positive environment for all employees through mutual respect and tolerance.

Lund University is a governmental authority, which means you get special benefits, generous holidays and a favourable occupational pension. We also have a flexible time agreement that creates good conditions for a balance between work and leisure.

Read more on the university's website about being employed at Lund University,  Work with us .

Work duties

The postdoctoral researcher will conduct statistical analyses of high-dimensional data collected from healthy control individuals and patients with Alzheimer's disease and other neurodegenerative diseases. The analyses will particularly focus on proteomics, both in our own large cohorts led from Lund and Malmö and in cohorts from other sources that we analyze in various collaborations. We utilize state-of-the-art proteomic methods, such as OLINK Explore HT, SomaScan, and NULISA. The project also involves integrative omics analyses, where proteomic data can be analyzed alongside genetics, metabolomics, and quantitative neuroimaging and neuropathology. The research will primarily consist of statistical analyses, writing scientific articles, and presenting results at national and international conferences. The majority of the research is conducted in collaboration with other members of the group. Other tasks within the research group may also be relevant.

Eligibility

Appointment to a post-doctoral position requires that the applicant has a PhD, or an international degree deemed equivalent to a PhD, within the subject of the position. This eligibility requirement needs to be met no later than the time when the employment decision is made, and evidence that this requirement is met needs to have been sent in by this time at the latest. Candidates should have completed their PhD degree no more than three (3) years before the last date for applications. Under special circumstances, the doctoral degree can have been completed earlier. These circumstances refer to leave due to illness, parental leave, clinical work, positions of trust within trade union organizations or other similar circumstances.

Basis for assessment      

At Lund University, employment as a postdoctoral researcher provides opportunities for scientific and pedagogical merit. There is mainly room for merit in research, but also for certain higher education pedagogical training. Teaching may be included in the tasks.

For the employment as a postdoctoral research, scientific ability will primarily be taken into account.

Qualifications

Requirements:

• Completed PhD in engineering, bioinformatics, genetics, statistics, computer science, mathematics, computational biology, or a related discipline
• Good knowledge of bioinformatics/statistical programming, eg in R, Python, or MATLAB
• Experience with high-performance computing (HPC) environments and/or parallelized job submission
• Good knowledge of oral and written communication in English
• Very good communication, presentation and writing skills
• Good cooperation skills, and ability to work independently
• Good analytical and initiative skills

Meritorious:

• Specific interest and experience in neurodegenerative diseases or aging

Terms of employment

This is a full-time employment limited to 2 years, with a possible extension for up to one additional year. Preliminary start date 2024-06-01 or according to agreement. The period of employment is determined in accordance with the agreement “Avtal om tidsbegränsad anställning som postdoktor” (“Agreement on fixed-term employment as a post-doctoral researcher”) between SACO-S, OFR/S and SEKO, dated November 19, 2021.

How to apply

The position is sought via the university’s recruitment system. Applications must include a personal motivation letter, in which you describe how you meet the qualification requirements and why you are interested in the position. The application must also contain a CV, contact information of two references, a diploma (including a grade transcript) and other documents you wish to be considered (e.g. letters of recommendation and list of publications).

The Faculty of Medicine is a part of Lund University, and is responsible for education and research within medicine and healthcare. Our academic programs are closely linked with the healthcare system and are firmly anchored in the faculty’s strong research tradition. Our research spans a broad field within experimental preclinical research, near-patient clinical research and health sciences research. The Faculty of Medicine, with its 1,800 employees and 2,700 students in Lund and Malmö, is a knowledge-intensive meeting place for students, teachers and researchers from all over the world.

The Department of Clinical Sciences, Malmö is one of the six departments at the Faculty of Medicine, Lund University. We have a strong focus on clinical and epidemiological research and also conduct an extensive preclinical laboratory research.

We kindly decline all sales and marketing contacts.

• Type of employment Temporary position
• Contract type Full time
• First day of employment 1st of June 2024 or according to agreement
• Salary Monthly salary
• Number of positions 1
• Full-time equivalent 100
• County Skåne län
• Country Sweden

Reference number PA2024/769

• Oskar Hansson, professor, forskargruppschef,  [email protected]
• Niklas Mattsson-Carlgren, universitetslektor,  [email protected]
• Jacob Vogel, biträdande universitetslektor,   [email protected]
• Linnea Gard, HR-partner, [email protected]

Union representative

• OFR/ST:Fackförbundet ST:s kansli, 046-2229362
• SACO:Saco-s-rådet vid Lunds universitet, [email protected]
• SEKO: Seko Civil, 046-2229366

Published 19.Mar.2024

Last application date 12.May.2024 11:59 PM CEST

Share this job

Get job alerts

Create a job alert and receive personalised job recommendations straight to your inbox.

Similar jobs

Senior research associate (m/f/d) - permanent position - institut of neuropathology.

• Essen, Nordrhein-Westfalen (DE)

Postdoctoral Fellow in Cancer Bioinformatics (f/m/x)

• Cologne, Nordrhein-Westfalen (DE)

Postdoctoral Scholar - Department of Physiology

• Memphis, Tennessee

• Campus News /

Dr. Jimmy Feix Receives R21 to Study Parkinson's Disease

April 24, 2024

Jimmy B. Feix, PhD , professor of biophysics , was awarded a two-year, $429,000 R21 grant from the National Institute of Neurological Disorders and Stroke to investigate probiotic treatment to mitigate levodopa (L-dopa) metabolism by the gut metabolism as a promising novel approach to enhance the effectiveness of oral L-dopa therapy in Parkinson’s disease (PD).

PD is a progressive neurodegenerative disease resulting from the loss of dopaminergic neurons in the substantia nigra. It is the second-leading neurodegenerative disease associated with aging. For over fifty years, treatment with L-dopa, which crosses the blood-brain barrier and is converted to dopamine, has been used to mitigate the debilitating motor symptoms associated with PD. However, there are several caveats associated with L-dopa therapy. The scientific impact of these studies will be to further elucidate the effects of gut microbial metabolism on the efficacy of oral L-dopa therapy. There is a clear unmet need for novel approaches that enhance or extend the usefulness of L-dopa in PD treatment, and the development of a probiotic that effectively prevents decarboxylation of L-dopa in the gastrointestinal tract may have significant potential as an adjunct to L-dopa in the management of PD.

Collaborators on the project include Cecilia J. Hillard, PhD ; associate dean for research, professor of pharmacology & toxicology, director of the Neuroscience Research Center, and G. Frederick Kasten, Jr. Endowed Chair in Parkinson’s Disease Research; Christopher J. Kristich, PhD , professor of microbiology & immunology and director of the Center for Infectious Disease Research; and Nita H. Salzman, MD, PhD , professor of pediatrics and microbiology & immunology, director of the Medical Scientist Training Program, and founding director of the Center for Microbiome Research.

• Future Leaders in Neurology
• ACTRIMS 2024
• Treating NMOSD: What's Next?

• Conferences
• Publications

Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhD

The chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]

WATCH TIME: 6 minutes

"The consistency of this mechanism across models, whether it's animal models of Alzheimer, ALS, or Parkinson, shows that it promotes HGF signaling, leading to consistent benefits in both motor and cognitive function. So, we're very confident that there is potential in this mechanism and excited to see if it translates in the clinic."

Neurotrophic factor systems, including hepatocyte growth factors (HGFs), are expressed in neurons and glia, which play key roles in maintaining neuronal survival, connectivity, metabolic stability, and regulating inflammation. Promotion of the HGF signaling to improve these effects may show promise in neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS). In the past years, Athira Pharma has developed first generation (fosgonimeton) and second generation (ATH-1020 and ATH-1105) small molecules aimed to promote neurotrophic HGF system activity in these neurodegenerative disorders.

In recent studies, findings demonstrated neurotrophic, neuroprotective, and anti-inflammatory effects of positive modulators of the HGF system with fosgonimeton, ATH-1020, or ATH-1105 in preclinical models of AD, PD, and ALS, respectively. 1 In these, investigators assessed neuroprotective effects in primary neurons exposed to various insults including amyloid-β, α-synuclein protofibrils, mitochondrial toxins, excitotoxic glutamate, or proinflammatory lipopolysaccharide. Overall, the findings showed consistent treatment effects across diverse models of neurodegenerative disorders and supported the broad therapeutic potential of targeting neurotrophic HGF signaling.

Kevin Church, PhD , chief scientific officer at Athira, presented these results at the 2024 American Academy of Neurology (AAN) Annual Meeting , held April 13-18, in Denver, Colorado. At the meeting, Church sat down with NeurologyLive ® in an interview to discuss how HGF compounds target neurotrophic deficits in neurodegenerative diseases such as AD, PD, and ALS. He also spoke about the key findings regarding the impact of HGF compounds on PD and shared some of the upcoming milestones for clinical trials in AD and ALS programs.

Click here for more coverage of AAN 2024.

REFERENCES 1. Church K, Reda S, Berthiaume A, et al. Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders. Presented at: 2024 AAN Annual Meeting; April 13-18; Denver, CO.

Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia

Episode 113: Lessons Learned in Alzheimer Drug Development

Investigational Agent EDG-5506 Shows Promising 2-Year Data in Becker Muscular Dystrophy

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease

Researchers Identify Distinct Differences in Acute Optic Neuropathy of MOGAD vs Nonarterior Anterior Ischemic Optic Neuropathy

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya Therapeutics Xtalks Life Science Podcast

• Life Sciences

In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021.  Dr. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify and bridge both disciplines. Dr. Berman gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and Eli Lilly. Dr. Berman received a Bachelor in Biology from the University of Michigan and a Masters and PhD in Neuroscience and Pharmacology from Weill Cornell Medical School. Tune into the episode to learn more about Coya Therapeutics and its Treg-targeted therapies program. The company’s current pipeline includes its lead candidate product COYA 302, which is currently being evaluated in a clinical study for the treatment of amyotrophic lateral sclerosis (ALS).  For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/   Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

• More Episodes
• © 2024 Honeycomb Worldwide Inc.